Silence Therapeutics has been granted a patent for a compound that combines a modified saccharide moiety with a nucleic acid, useful for RNA interference therapy and research. The compound, particularly effective in treating liver disease, is represented by formula (II) in the patent claim. GlobalData’s report on Silence Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Silence Therapeutics Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Silence Therapeutics, was a key innovation area identified from patents. Silence Therapeutics's grant share as of April 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Compound for rna interference therapy in treating liver disease

Source: United States Patent and Trademark Office (USPTO). Credit: Silence Therapeutics Plc

A recently granted patent (Publication Number: US11912993B2) discloses a compound with a specific chemical formula designed for the delivery of nucleic acids to hepatocytes. The compound, represented by formula (II), includes a saccharide and various alkylene groups, offering a novel approach for targeted delivery within the body. Additionally, the patent claims cover the use of this compound in compositions with carriers or excipients, as well as methods for treating subjects suffering from a range of conditions such as liver disease, genetic disorders, and metabolic diseases.

Furthermore, the patent outlines in vitro methods for delivering nucleic acids to hepatocytes using the disclosed compound, highlighting its potential applications in treating rare diseases like acromegaly, metabolic disorders such as hypercholesterolemia, and liver injuries induced by drugs. The comprehensive scope of the patent extends to encompassing methods of treatment involving the administration of the compound-containing compositions to subjects in need, emphasizing its versatility in addressing various health conditions. Overall, the patent provides a detailed framework for utilizing the compound in therapeutic interventions, particularly focusing on liver-related ailments and genetic disorders, showcasing its potential impact in the field of medicine.

To know more about GlobalData’s detailed insights on Silence Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies